2008-10 to 2010-12 Joint PhD: Karolinska Institute
2007-09 to 2010-12 PhD: Jilin University
2004-09 to 2007-06 Master's: Jilin University
2000-09 to 2004-06 Bachelor's: Jilin University
2013-10 to 2016-06 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2013-07 to 2013-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
2011-05 to 2013-06 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
2008-10 to 2010-12 - Karolinska Institute - Joint PhD
2007-09 to 2010-12 - Jilin University - PhD
2004-09 to 2007-06 - Jilin University - Master's
2000-09 to 2004-06 - Jilin University - Bachelor's
Research
Pharmacology Oncology Pharmacology
Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities, 9th Author, 2022
Discovery of a series of 1H-pyrrolo2,3-bpyridine compounds as potent TNIK inhibitors, 4th Author, 2021
Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1, 9th Author, 2021
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction, 12th Author, 2020
Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter, 4th Author, 2020
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors, 17th Author, 2019
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l -kynurenine, 8th Author, 2019
New microtubulin inhibitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis, 7th Author, 2018
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties, 6th Author, 2018
New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis, 4th Author, 2018
Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups, 2nd Author, 2018
Low, but not high, dose caffeine is a readily available probe for adenosine actions, 3rd Author, 2017
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, 6th Author, 2017
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, 9th Author, 2017
Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor, 2nd Author, 2017
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced invivo efficacy for cancer therapy, 10th Author, 2017
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy, 5th Author, 2017
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy, 1st Author, 2016
Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44, 5th Author, 2016
Dual targeting of microtubule and topoisomerase II by alpha-carboline derivative YCH337 for tumor proliferation and growth inhibition, 10th Author, 2015
Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1�� accumulation in both endothelial and tumor cells, 3rd Author, 2015
Dual targeting of microtubule and topoisomerase II by ��-carboline derivative YCH337 for tumor proliferation and growth inhibition, 10th Author, 2015
Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1a accumulation in both endothelial and tumor cells, 3rd Author, 2015
丹参酮Ⅰ抗血管生成作用和机制研究, 3rd Author, 2015
Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization, 2nd Author, 2015
Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization, 2nd Author, 2015
Energy homeostasis in mice lacking adenosine receptors, 1st Author, 2014
MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189, 2nd Author, 2014
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy, 1st Author, 2013
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy, 1st Author, 2013
Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain, 4th Author, 2013
Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II, 3rd Author, 2012
Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs, Not mentioned, 2012
Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs, 2nd Author, 2012
Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model, 4th Author, 2012
Chapter 3 - Adenosine and the Regulation of Metabolism and Body Temperature, 3rd Author, 2011
Adenosine A(1) receptors and vascular reactivity, Not mentioned, 2010
Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury, 3rd Author
Area of Focus
3D Genomics | Epigenetics | Transcriptional Regulation | Cardiovascular Diseases | Cancer | Human Diseases | Molecular Biology | Cellular Medicine | Genetic Analysis | Disease Mechanisms
